Method of overcoming therapeutic limitations of non-uniform distribution of radiopharmaceuticals and chemotherapy drugs

• US 10,295,543 B2
• Filed: 03/10/2016
• Issued: 05/21/2019
• Est. Priority Date: 06/23/2006
• Status: Active Grant

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Howell, Roger W., Akudugu, John M., Pasternack, Jordan B., Neti, Venkata S.
• Primary Examiner(s): Lin, Jerry
• Application Number:
  US15/066,347
• Publication Number:
  US 20160258963A1
• Time in Patent Office: 1,167 Days
• Field of Search: 702 19
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 51/0402 carboxylic acid carriers, fatty acids amino acids A61K51/0406
• CPC Class Codes: A61K 51/1051 the tumor cell being from breast, e.g. the antibody being herceptin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/60 involving radioactive labelled substances

Abstract

Therapeutic compositions for treating diseased cells such as cancer cells in a patient, formulated from a plurality of therapeutic agents selected from radiopharmaceuticals, chemotherapeutic agents and radionuclide labeled antibodies. Methods for predicting the response of an individual patient'"'"'s cells to therapeutic intervention are also disclosed.

Claims

1. A therapeutic composition for treating diseased cells in a patient comprising a plurality of therapeutic agents selected from the group consisting of radiopharmaceuticals, chemotherapeutic agents and radionuclide labeled antibodies, wherein the selection of and the relative concentrations of the therapeutic agents in the composition is determined by a method including the steps of:

(a) exposing populations of the diseased cells to increasing concentrations of combinations of the therapeutic agents, to increasing concentrations of the individual therapeutic agents, or both;

(b) measuring the incorporation by cellular uptake of the therapeutic agents or the therapeutic agent combinations;

(c) plotting the number of cells vs the amount of incorporated therapeutic agents to obtain distribution plots for the cell populations;

(d) predicting the surviving fractions of the cell populations employing a simulation that uses the therapeutic agent distribution plots and a function that expresses the probability that a given cell will survive a given amount of an incorporated therapeutic agent; and

(e) selecting the therapeutic agent combination and relative concentration of each agent within the selected combination predicted to be most lethal.

2. The composition of claim 1 wherein said simulation comprises a Monte Carlo simulation.

3. The composition of claim 2, wherein the Monte Carlo simulation accounts for the amount of each agent in each cell and the results are used to identify the most effective combination of therapeutic agents, and their therapeutically optimal doses in combination.

4. The composition of claim 1, wherein said individual patient'"'"'s cells comprise cancer cells.

5. The composition of claim 1, wherein said incorporation of said therapeutic agent is measured using a high-speed technique.

6. The composition of claim 5, wherein said high-speed technique comprises fluorescence spectroscopy.

7. The composition of claim 6, wherein the fluorescence measurement comprises the mean fluorescence intensity (MFI).

8. The composition of claim 5, wherein the high-speed technique for assaying therapeutic agent incorporation on a cell-by-cell basis comprises flow cytometry.

9. The composition of claim 5, wherein the high-speed technique for assaying therapeutic agent incorporation on a cell-by-cell basis comprises fluorescence microscopy or laser scanning microscopy.

10. The composition of claim 2, wherein said Monte Carlo simulation comprises flow-cytometry-assisted Monte Carlo simulation.

11. The composition of claim 2, wherein said Monte Carlo simulation comprises fluorescence microscope-assisted Monte Carlo simulation or laser scanning microscope-assisted Monte Carlo simulation.

12. The composition of claim 1, wherein the therapeutic agents are selected from a plurality of radionuclide labeled antibodies, and the relative concentrations of the radionuclide labeled antibodies in the composition is determined by a method including the steps of:

(a) exposing populations of the diseased cells to increasing concentrations of combinations of the radionuclide labeled antibodies, to increasing concentrations of the individual radionuclide labeled antibodies, or both;

(b) measuring the incorporation by cellular uptake of the radionuclide labeled antibodies or the radionuclide labeled antibody combinations;

(c) plotting the number of cells vs the amount of incorporated antibodies to obtain distribution plots for the cell populations;

(d) predicting the surviving fractions of the cell populations employing a simulation that that uses the calculated incorporation of the antibodies in each cell and a function that expresses the probability that a given cell will survive upon incorporating a cellular radiation dose characteristic of the radionuclide of the incorporated antibody; and

(e) selecting the radionuclide labeled antibody combination and relative concentration of each antibody within the selected combination predicted to be most lethal.

13. The composition of claim 12, wherein said simulation comprises a Monte Carlo simulation.

14. The composition of claim 13, wherein the Monte Carlo simulation accounts for the amount of each agent in each cell and the results are used to identify the most effective combination of therapeutic agents, and their therapeutically optimal doses in combination.

15. The composition of claim 12, wherein said individual patient'"'"'s cells comprise cancer cells.

16. The composition of claim 13, wherein said Monte Carlo simulation comprises flow-cytometry-assisted Monte Carlo simulation, fluorescence microscope-assisted Monte Carlo simulation or laser scanning microscope-assisted Monte Carlo simulation.

17. The composition of claim 1, wherein the therapeutic agents are selected from a plurality of radionuclide labeled antibodies, and the relative concentrations of the radionuclide labeled antibodies in the composition is determined by a method including the steps of:

(a) exposing populations of the diseased cells to increasing concentrations of combinations of the radionuclide labeled antibodies, to increasing concentrations of the individual radionuclide labeled antibodies, or both;

(b) determining the number of antibodies bound to individual diseased cells;

(c) predicting the surviving fractions of the cell populations employing a simulation that that uses the therapeutic agent distribution plots and a function that expresses the probability that a given cell will survive a given amount of an incorporated therapeutic agent; and

(d) selecting the therapeutic agent combination and relative concentration of each agent within the selected combination predicted to be most lethal.

18. The composition of claim 17, wherein determining the number of antibodies bound to individual diseased cells is accomplished by the steps of (i) measuring fluorescence intensity and (ii) calculating absorbed dose to each cell.

19. The composition of claim 18, wherein the step (i) of measuring fluorescence intensity utilizes Bang'"'"'s beads.

20. The composition of claim 18, wherein the simulation comprises a Monte Carlo simulation.

21. The composition of claim 20, wherein the Monte Carlo simulation is modified to account for specific activity of the antibodies.

22. The composition of claim 20, wherein the Monte Carlo simulation is further modified to account for the calculated absorbed dose to each cell.

23. The composition of claim 17 wherein the diseased cells comprise cancer cells.